Table 2.

Polyamine Metabolites in Cohort B Patients

Compound Name	Comparative Analysis
	PD/Control		De Novo PD/Control		PSP/Control		AD/Control
	Ratio	p	Ratio	p	Ratio	p	Ratio	p
DiAcSpd	2.77	<0.0001	1.95	0.134	1.93	<0.0001	1.51	0.0811
N1‐AcSpd	1.46	<0.0001	0.850	0.661	1.74	0.0002	1.11	0.237
N8‐AcSpd	1.55	<0.0001	1.09	0.968	1.89	<0.0001	1.53	0.0006
DiAcSpm	1.59	<0.0001	0.892	1.00	1.65	0.0001	2.11	0.0763
Spd	1.80	<0.0001	1.57	0.0764	1.05	1.00	1.02	0.886
N1‐AcSpm	0.945	0.302	0.770	0.404	1.43	0.0012	1.05	0.999
Spm	0.762	0.0468	0.776	0.951	1.21	0.223	0.563	0.0013
Spm/Spd ratio	0.459	<0.0001	0.515	0.106	1.43	0.154	0.544	<0.0001

Probability values were obtained by Steel test between healthy controls and each disease.

AD = Alzheimer disease; DiAcSpd = N1,N8‐diacetylspermidine; DiAcSpm = N1,N12‐diacetylspermine; N1‐AcSpd = N1‐acetylspermidine; N1‐AcSpm = N1‐acetylspermine; N8‐AcSpd = N8‐acetylspermidine; PD = Parkinson disease; PSP = progressive supranuclear palsy; Spd = spermidine; Spm = spermine.